Vinblastine, methotrexate, bleomycin, in the management of head and neck cancer
- Vanhaelen, Christian
- Bertrand, Marcelle
- De Jager, Robert
- Kenis, Yvon
DOIAbstract
Fourty-three Forty-three with head and neck epidermoid carcinomas were treated with combination chemotherapy consisting of vinblastine (VLB) 4 mg/m2 i.v. methotrexate (MTX) 60 mg/m2 i.v. and bleomycin (BLM) 15 mg i.v. day 1 and 8, every 28 days. Dose limiting toxicity was clearly hematological: leukopenia was more severe than thrombopenia and 5 patients died of septicemia associated with WBC 50% decrease in tumor size) for a median duration of 4 months. Stabilisation of disease (no change or regression <50%) was seen in 8 (23%), progression of disease in 8 (23%), early death in 3 (9%) and toxic death in 5 (15%) patients. Although some long lasting complete remissions were seen in head and neck cancer patients streated with this regimen, it ...
Add to ORKG